You are here: Industry Insights > NVX-CoV2373

News List

Novavax files for Conditional Marketing Authorisation of COVID-19 vaccine in Switzerland ExpressPharma
February 15, 2022
The submission for the regulatory evaluation of the vaccine includes data from two phase-III clinical trials.
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine prnasia
February 15, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Singapore Health Sciences Authority...
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial prnasia
February 14, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373...
Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain* prnasia
February 07, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency...
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine prnasia
February 07, 2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases...
DCGI grants EUA to Novavax’s Covid-19 vaccine Pharmaceutical-Technology
December 29, 2021
The Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) to Novavax’s Covid-19 vaccine, NVX-CoV2373, with Matrix-M adjuvant to prevent Covid-19 in adults aged 18 years and older.
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India prnasia
December 29, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute...
Novavax and SK bioscience Expand Manufacturing Agreement prnasia
December 24, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience...
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies prnasia
December 23, 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced initial data evaluating the immune response of its COVID-19 vaccine...
Novavax gets EC marketing authorization for Covid-19 vaccine By PBR Staff Writer Pharmaceutical-Business-Review
December 22, 2021
Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial SARS-CoV-2 virus strain.

Previous page 1 2 3 4 5 6 7 Next page